Form 4: VolitionRx Director Alan Colman Receives Restricted Stock Units in Lieu of Cash Compensation

Director Alan Colman of VolitionRx Ltd. was granted 12,972 restricted stock units (RSUs) in lieu of cash compensation.

Summary

• Alan Colman, a director at VolitionRx Ltd., received 12,972 restricted stock units (RSUs) on December 1, 2024.
• These RSUs were granted in place of cash compensation that would have otherwise been paid to Mr. Colman.
• The RSUs vest in three equal installments of 4,324 units on December 1, 2024, January 1, 2025, and February 1, 2025.
• An additional vesting of all units is scheduled for July 1, 2025, subject to continued service.
• Upon vesting, Mr. Colman will receive common stock equal to the number of vested RSUs.
• Following this transaction, Mr. Colman beneficially owns 230,524 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive for aligning interests, but does not indicate any significant positive or negative news.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the RSUs is dependent on the future performance of VolitionRx's stock price.
• The vesting of the RSUs is contingent on continued service, which could be a risk if the director leaves the company.

Future Outlook

The director's future compensation will be tied to the performance of the company's stock through the vesting of the RSUs.

Industry Context

The use of stock-based compensation is a common practice in the biotechnology industry to align the interests of management and shareholders.

Comparison to Industry Standards

• Granting restricted stock units to directors is a standard practice in many publicly traded companies, particularly in the biotech sector.
• The vesting schedule of the RSUs is typical, with multiple tranches over a period of time to incentivize continued service.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also use similar stock-based compensation plans for their directors and executives.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign of aligning director interests with company performance.
• Employees may see this as a standard practice for director compensation.

Key Dates

Keywords

restricted stock units, RSUs, stock compensation, director, insider trading, beneficial ownership, VolitionRx, VNRX